Results 251 to 260 of about 1,320,527 (284)

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2005
Syntheses and SAR studies of 3,3-bisaryloxindole analogues provided potent mineralocorticoid receptor (MR) antagonists that were selective over other steroid nuclear hormone receptors.
David A, Neel, Matthew L, Brown, Peter A, Lander, Timothy A, Grese, Jean M, Defauw, Robert A, Doti, Todd, Fields, Sally Ann, Kelley, Stephon, Smith, Karen M, Zimmerman, Mitchell I, Steinberg, Prabhakar K, Jadhav   +11 more
openaire   +2 more sources

The cardioprotective effects of mineralocorticoid receptor antagonists

Pharmacology & Therapeutics, 2014
Despite state-of-the-art reperfusion therapy, morbidity and mortality remain significant in patients with an acute myocardial infarction. Therefore, novel strategies to limit myocardial ischemia-reperfusion injury are urgently needed. Mineralocorticoid receptor (MR) antagonists are attractive candidates for this purpose, since several clinical trials ...
van den Berg, T.N.A., van den Berg, T.N.A., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Frohlich, G.M., Deinum, J., Deinum, J., Hausenloy, D.J., Riksen, N.P., Riksen, N.P., Riksen, N.P., Riksen, N.P.   +12 more
openaire   +3 more sources

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Current Pharmaceutical Design, 2019
Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos, Christodoulos, Papadopoulos, Konstantinos, Koutsampasopoulos, Georgios, Lales, Christos, Mitas, Michael, Doumas   +5 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?

Current Hypertension Reports, 2004
Accumulating evidence indicates that aldosterone is involved in cardiovascular disease by inducing inflammation in the presence of moderate amounts of salt in the diet. Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension.
Olga, Gumieniak, Gordon H, Williams
openaire   +2 more sources

The renal effects of mineralocorticoid receptor antagonists

International Journal of Cardiology, 2015
Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests that aldosterone contributes to the pathogenesis and progression of kidney disease. The binding of aldosterone on epithelial and non-epithelial cells of the kidney induces many deleterious effects, such ...
Stefano, Bianchi, Valentina, Batini, Roberto, Bigazzi   +2 more
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone

Current Cardiology Reports, 2020
We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects.MRAs are well known for ...
Juan Simon, Rico-Mesa, Averi, White, Ashkan, Ahmadian-Tehrani, Allen S, Anderson   +3 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists in kidney transplantation

European Journal of Clinical Investigation
AbstractBackgroundThe fundamental role of the renin–angiotensin–aldosterone system in the pathophysiology of chronic kidney disease, congestive heart failure, hypertension and proteinuria is well established in pre‐clinical and clinical studies. Mineralocorticoid receptor antagonists are among the primary options for renin–angiotensin–aldosterone ...
Mehmet Kanbay, Sidar Copur, Berk Mizrak, Francesca Mallamaci, Carmine Zoccali   +4 more
openaire   +2 more sources

Role of mineralocorticoid receptor antagonists in kidney diseases

Drug Development Research, 2020
AbstractMineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic kidney disease.
Vishal Patel, Amit Joharapurkar, Mukul Jain   +2 more
openaire   +2 more sources

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology & Metabolism, 2015
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, Zannad, Faiez   +5 more
openaire   +2 more sources